Literature DB >> 3755439

Neuropeptide Y induces and modulates vasoconstriction in intracranial and peripheral vessels of animals and man.

J H Hanko, K Törnebrandt, J E Hardebo, J Kåhrström, A Nobin, C Owman.   

Abstract

Neuropeptide Y (NPY) has recently been reported to coexist with noradrenaline (NA) in central as well as peripheral noradrenergic nerves. NPY-containing nerve fibres are particularly numerous around blood vessels. Studies were performed on isolated pial arteries as well as on arteries and veins from several peripheral vascular beds from rabbit, cat and man. NPY induced a varying degree of direct contraction of the vessels with an EAm up to 15 mN. Pial arteries were more sensitive than peripheral arteries to NPY (mean EC50 = 7.6 X 10(-9) M). The presence of NPY did not cause any consistent or significant potentiation of the contractile response to NA in any of the vessels tested. Transmural electrical stimulation of the perivascular nerves (including blockade with tetrodotoxin) was performed mainly with auricular artery from the rabbit. Blocking experiments confirmed that the neurogenic contraction was mediated by noradrenergic-type fibres. NPY caused a concentration-related potentiation of the neurally evoked contractile response. The peptide also potentiated the tetrodotoxin-resistant probably non-neurogenic contractions obtained during enhanced electrical field stimulation. It is concluded that NPY interacts with NA during sympathetic nerve activation primarily through a presynaptic effect.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3755439     DOI: 10.1111/j.1474-8673.1986.tb00638.x

Source DB:  PubMed          Journal:  J Auton Pharmacol        ISSN: 0144-1795


  8 in total

1.  Potentiation by neuropeptide Y of vasoconstriction in rat resistance arteries.

Authors:  R Andriantsitohaina; J C Stoclet
Journal:  Br J Pharmacol       Date:  1988-10       Impact factor: 8.739

2.  Gender-modulated endogenous baseline neuropeptide Y Y1-receptor activation in the hindlimb of Sprague-Dawley rats.

Authors:  Dwayne N Jackson; Kevin J Milne; Earl G Noble; J Kevin Shoemaker
Journal:  J Physiol       Date:  2004-10-28       Impact factor: 5.182

3.  Effect of neuropeptide Y on adrenergic and non-adrenergic, non-cholinergic responses in the rat anococcygeus muscle.

Authors:  E Vila; A Tabernero; F Fernandes; M Salaices
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

4.  Effects of neuropeptide Y and vasoactive intestinal peptide on human venous smooth muscle in vivo.

Authors:  M Wolzt; W Gerschlager; B Zweytick; B Jilma; H Riemer; K Sertl; H G Eichler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-08       Impact factor: 3.000

5.  Cardiac neuropeptide Y and noradrenaline balance in patients with congestive heart failure.

Authors:  Q P Feng; T Hedner; B Andersson; J M Lundberg; F Waagstein
Journal:  Br Heart J       Date:  1994-03

6.  Influence of estradiol supplementation on neuropeptide Y neurotransmission in skeletal muscle arterioles of F344 rats.

Authors:  Kirk W Evanson; Audrey J Stone; Enoch Samraj; Tyler Benson; Rhonda Prisby; Heidi A Kluess
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2012-07-25       Impact factor: 3.619

Review 7.  Peptides in the mammalian cardiovascular system.

Authors:  J Wharton; S Gulbenkian
Journal:  Experientia       Date:  1987-07-15

8.  Enhancement by neuropeptide Y (NPY) of the dihydropyridine-sensitive component of the response to alpha 1-adrenoceptor stimulation in rat isolated mesenteric arterioles.

Authors:  R Andriantsitohaina; J C Stoclet
Journal:  Br J Pharmacol       Date:  1990-02       Impact factor: 8.739

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.